Details of the Drug Reposition

General Information of This Drug (ID: DMMQ2U9)

Drug Name
VGX-3100   DMMQ2U9

Information on Drug Reposition of This Drug

Molecular Interaction Atlas (MIA)
2 Phase 3 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Cervical Intraepithelial neoplasia DISXP757 2E66.1 Phase 3 [1]
Dysplasia DISHPNVX LB30-LD2F Phase 3 [2]
------------------------------------------------------------------------------------
2 Phase 2 Indication(s)
Indication Name Indication ID ICD-11 Status REF
Human papillomavirus infection DISX61LX 1A9Y Phase 2 [3]
Vulvar intraepithelial neoplasia DISA474V 2E67.10 Phase 2 [2]
------------------------------------------------------------------------------------

References

1 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
2 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3 ClinicalTrials.gov (NCT01304524) A Study of VGX-3100 DNA Vaccine With Electroporation in Patients With Cervical Intraepithelial Neoplasia Grade 2/3 or 3. U.S. National Institutes of Health.